Drugs / Irosustat
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00790374 | Jan 2009 → Oct 2010 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 1 | NCT01840488 | Apr 2007 → Sep 2010 | female breast carcinoma | Ipsen | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01785992 | Oct 2012 → Dec 2014 | breast cancer | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT01662726 | Aug 2012 → Jul 2014 | breast neoplasm | Imperial College London | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01230970 | May 2011 | breast cancer | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT01251354 | Nov 2010 → Jun 2011 | endometrial cancer | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT00910091 | Aug 2009 → Jan 2012 | endometrial cancer | Ipsen | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irosustat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01662726 ↗ |
| Known as | 667 COUMATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL286738 ↗ |
| Known as | BN83495 | “The purpose of this study is to determine the optimal biological dose (OBD) of Irosustat (BN83495) in postmenopausal women with oestrogen receptor (ER) positive locally...” NCT01840488 ↗ |
| Known as | STX 64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL286738 ↗ |
| Action | Inhibit | “Oral Steroid Sulphatase Inhibitor BN83495” NCT00910091 ↗ |
| Modality | Small molecule | — CHEMBL286738 ↗ |
| Route | Oral | “daily oral administration” NCT00790374 ↗ |
| Target | STS | “inhibition of steroid sulphatase (STS) activity.” NCT01230970 ↗ |